CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 6 enrolled
Drug / intervention
haNK™ for Infusionbiological
Likely dose
Not specified in trial documentationAI-extracted
Key inclusion· 7
  • ✓Histologically confirmed, unresectable, locally advanced or metastatic solid malignancy
  • ✓ECOG performance status 0-2
  • ✓At least 1 measurable lesion and/or non-measurable disease evaluable per RECIST v1.1
  • ✓Received ≥1 prior therapy line in metastatic setting or not candidate for proven therapy
Key exclusion· 10
  • ✕History of persistent grade ≥2 hematological toxicity from prior therapy
  • ✕Serious uncontrolled concomitant disease or high risk for treatment complications
  • ✕Systemic autoimmune disease (lupus, rheumatoid arthritis, Addison's, lymphoma-associated)
  • ✕History of organ transplant requiring immunosuppression

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03027128
NCT03027128Phase 1Completed
CompareCT.gov

Open-label, Phase 1 Study of haNK™ for Infusion in Subjects With Metastatic or Locally Advanced Solid Tumors

ImmunityBio, Inc.·interventional·Posted Jan 20, 2017·Updated Nov 20, 2024

In Brief

A Phase 1 clinical trial evaluating haNK™ for Infusion for Solid Tumor. Completed, enrolled 6 participants across 1 site.

Detailed Summary

The purpose of this study is to determine whether haNK™ for Infusion is safe and effective in the treatment of metastatic or locally advanced solid tumors.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumor
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
2017201820192020202120222023202420252026
First PostedJan 20, 2017
Enrollment StartAug 2, 2017
Primary CompletionMay 6, 2019
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 9.5 years ago

Interventions

haNK™ for Infusionbiological

haNK™ for Infusion is a human, allogeneic, NK cell line that has been engineered to produce endogenous, intracellularly retained IL-2 and to express CD16, the high-affinity (158V) Fc gamma receptor (FcγRIIIa/CD16a).